Cipla is currently trading at Rs. 397.30, up by 3.70 points or 0.94% from its previous closing of Rs. 393.60 on the BSE.
The scrip opened at Rs. 385.00 and has touched a high and low of Rs. 432.00 and Rs. 372.30 respectively. So far 96739 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 585.50 on 27-May-2019 and a 52 week low of Rs. 356.75 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 432.00 and Rs. 363.85 respectively. The current market cap of the company is Rs. 30721.60 crore.
The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 41.17% and 22.16% respectively.
Hyderabad-based CSIR-Indian Institute of Chemical Technology (IICT) has partnered with Cipla to work on development of anti- viral drugs to contain COVID-19. Research on anti-viral drugs has been on throughout the world for long and many companies have developed molecules having anti-viral properties. But due to lack of demand, these molecules were not widely marketed. However, the CSIR-IICT decided to work on three such molecules -- remdesivir, favipiravir and baloxavir.
Cipla urged the IICT director S Chandrasekhar to start work on these molecules on an immediate basis. Cipla would upscale the process on the basis of know-how given by CSIR-IICT.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1850.40 |
| Dr. Reddys Lab | 1310.50 |
| Cipla | 1365.25 |
| Zydus Lifesciences | 939.10 |
| Lupin | 2442.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: